In 2015, Sanofi's layout in the Chinese market is quietly changing.
From 2014 to 2020, Sanofi will plan to have 18 new products on the market globally, and one-third of these key products are drugs that have about diabetes treatment.
The move is undoubtedly a move to capitalize on China's vast chronic disease market. According to statistics from the Ministry of Health and the National Development and Reform Commission in 2014, the medical consumption of China's 260 million chronic patients was already as high as $3 trillion.
Liang Xiaofeng, deputy director of the China Center for Disease Control and Prevention (CDC), said that aging and urbanization are the main reasons for the sharp increase in the prevalence of chronic diseases, which has grown unabated in the past two years.
"A country the size of China will have a lot of unmet medical needs. The fact that 30 percent of the world's published academic articles in biomedicine come from China, and 15 percent of all patents come from China, speaks volumes about China's potential. Long believes that China will soon become the world's second largest pharmaceutical market.
In addition to research and development, these multinational drug companies have also extended the tentacles of channel promotion to the Internet. In October this year, Sanofi and Health Road joined forces to create a mobile application platform for chronic disease management - Kang Sai, based on Internet mobile technology, is committed to creating doctor-patient communication, follow-up tools to enhance the level of disease management for patients with chronic diseases; the establishment of a platform for continuing education of doctors in the county to improve the awareness of the basic standardized diagnosis and treatment, and to help build the hierarchical diagnosis and treatment system, to truly realize the two-way referral.
These are the first steps in the process.